ImmPACT Bio to Participate at the 2024 Cell and Gene Meeting on the Mesa Conference
ImmPACT Bio to Participate at the 2024 Cell and Gene Meeting on the Mesa Conference LOS ANGELES, Calif., September 25, 2024 – ImmPACT Bio USA, Inc. (“ImmPACT Bio”), a clinical-stage company developing transformative logic-gate-based chimeric antigen receptor (CAR) T-cell therapies for treating cancer and autoimmune diseases, today announced that it will participate at the 2024 […]
ImmPACT Bio to Participate at Cell & Gene Therapy International 2024
ImmPACT Bio to Participate at Cell & Gene Therapy International 2024 LOS ANGELES, Calif., September 17, 2024 – ImmPACT Bio USA, Inc. (“ImmPACT Bio”), a clinical-stage company developing transformative logic-gate-based chimeric antigen receptor (CAR) T-cell therapies for treating cancer and autoimmune diseases, today announced that it will participate at the Cell & Gene Therapy International […]
ImmPACT Bio to Present New Preclinical Data for CD19/CD20 Bispecific CAR-T Cell Therapy in Multiple Sclerosis
ImmPACT Bio to Present New Preclinical Data for CD19/CD20 Bispecific CAR-T Cell Therapy in Multiple Sclerosis IMPT-514’s dual CAR approach is designed to ablate B-cells and pathogenic CD20+ T cells for potential therapeutic benefit in MS LOS ANGELES, May 21, 2024 – ImmPACT Bio USA Inc. (ImmPACT Bio), a clinical-stage biopharmaceutical company developing a new […]
ImmPACT Bio to Present New Ex Vivo Preclinical Data for Bispecific Claudin 18.2/TGF-β CAR T Program at the American Society of Gene & Cell Therapy 27th Annual Meeting
ImmPACT Bio to Present New Ex Vivo Preclinical Data for Bispecific Claudin 18.2/TGF-β CAR T Program at the American Society of Gene & Cell Therapy 27th Annual Meeting Novel dual CAR approach is designed to enhance CAR T-cell activity in solid tumors by addressing immune suppression in the tumor microenvironment LOS ANGELES, April 22, 2024 […]
ImmPACT Bio to Participate at the 2024 Cell and Gene Meeting on the Med Conference
ImmPACT Bio to Participate at the 2024 Cell and Gene Meeting on the Med Conference LOS ANGELES, Calif., March 26, 2024 – ImmPACT Bio USA, Inc. (“ImmPACT Bio”), a clinical-stage company developing transformative logic-gate-based chimeric antigen receptor (CAR) T-cell therapies for treating cancer and autoimmune diseases, today announced that it will participate at the 2024 […]
